Asset Details
Do you wish to reserve the book?
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
Do you wish to request the book?
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
2009
Overview
We conducted a systematic review and meta-analysis of randomized controlled trials that compared second-generation antipsychotic (SGA) drugs with placebo in schizophrenic patients and which considered 13 different outcome measures. Thirty-eight randomized controlled trials with 7323 participants were included. All SGA drugs were more effective than placebo, but the pooled effect size (ES) for overall symptoms (primary outcome) was moderate (−0.51). The absolute difference (RD) in responder rates was at 18% (41% responded to drug compared with 24% to placebo, number needed to treat=6). Similar ESs were found for the other efficacy parameters: negative symptoms (ES=−0.39), positive symptoms (ES=−0.48), depression (ES=−0.26), relapse (RD 20%) and discontinuation due to inefficacy (RD 17%). Curiously, the efficacy of haloperidol for negative and depressive symptoms was similar to that of the SGA drugs. In contrast to haloperidol, there was no difference in terms of EPS between any SGA drugs and placebo, and there was also no difference in terms of dropouts due to adverse events. Meta-regression showed a decline in treatment response over time, and a funnel plot suggested the possibility of publication bias. We conclude that the drug versus placebo difference of SGA drugs and haloperidol in recent trials was moderate, and that there is much room for more efficacious compounds. Whether methodological issues account in part for the relatively low efficacy ESs
and
the scarcity of adverse event differences compared with placebo needs to be established.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
Adult and adolescent clinical studies
/ Antipsychotic Agents - adverse effects
/ Antipsychotic Agents - therapeutic use
/ Biological and medical sciences
/ Drugs
/ Humans
/ Medicine
/ MEDLINE - statistics & numerical data
/ Pharmacology. Drug treatments
/ Placebos
/ Psycholeptics: tranquillizer, neuroleptic
/ Psychology. Psychoanalysis. Psychiatry
/ Psychotic Disorders - drug therapy
